Dr. Ari Baron, MD
Claim this profileAlta Bates Summit Medical Center-Herrick Campus
Expert in Parotid Gland Cancer
Studies Lung Cancer
30 reported clinical trials
68 drugs studied
Area of expertise
1Parotid Gland Cancer
Global LeaderStage IV
Stage III
BRAF negative
2Lung Cancer
Stage IV
Stage III
RET positive
Affiliated Hospitals
Clinical Trials Ari Baron, MD is currently running
Combination Therapy
for Multiple Myeloma
This phase III trial compares the combination of four drugs (daratumumab, bortezomib, lenalidomide and dexamethasone) to the use of a three drug combination (daratumumab, lenalidomide and dexamethasone). Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Chemotherapy drugs, such as lenalidomide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Daratumumab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Anti-inflammatory drugs, such as dexamethasone lower the body's immune response and are used with other drugs in the treatment of some types of cancer. Adding bortezomib to daratumumab, lenalidomide, and dexamethasone may be more effective in shrinking the cancer or preventing it from returning, compared to continuing on daratumumab, lenalidomide, and dexamethasone.
Recruiting2 awards Phase 332 criteria
Pembrolizumab + Olaparib
for Pancreatic Cancer
This phase II trial studies whether adding pembrolizumab to olaparib (standard of care) works better than olaparib alone in treating patients with pancreatic cancer with germline BRCA1 or BRCA2 mutations that has spread to other places in the body (metastatic). BRCA1 and BRCA2 are human genes that produce tumor suppressor proteins. These proteins help repair damaged deoxyribonucleic acid (DNA) and, therefore, play a role in ensuring the stability of each cell's genetic material. When either of these genes is mutated, or altered, such that its protein product is not made or does not function correctly, DNA damage may not be repaired properly. As a result, cells are more likely to develop additional genetic alterations that can lead to some types of cancer, including pancreatic cancer. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Olaparib is an inhibitor of PARP, a protein that helps repair damaged DNA. Blocking PARP may help keep tumor cells from repairing their damaged DNA, causing them to die. PARP inhibitors are a type of targeted therapy. The addition of pembrolizumab to the usual treatment of olaparib may help to shrink tumors in patients with metastatic pancreatic cancer with BRCA1 or BRCA2 mutations.
Recruiting1 award Phase 237 criteria
More about Ari Baron, MD
Clinical Trial Related8 years of experience running clinical trials · Led 30 trials as a Principal Investigator · 11 Active Clinical TrialsTreatments Ari Baron, MD has experience with
- Pembrolizumab
- Nivolumab
- Irinotecan Hydrochloride
- Fluorouracil
- Leucovorin Calcium
- Gemcitabine Hydrochloride
Breakdown of trials Ari Baron, MD has run
Parotid Gland Cancer
Lung Cancer
Non-Small Cell Lung Cancer
Pancreatic Cancer
Lung Carcinoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
What does Ari Baron, MD specialize in?
Is Ari Baron, MD currently recruiting for clinical trials?
Are there any treatments that Ari Baron, MD has studied deeply?
What is the best way to schedule an appointment with Ari Baron, MD?
What is the office address of Ari Baron, MD?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.